• Arrow International issued a nationwide recall of certain dialysis catheter kits that include Merit Medical’s 16F Dual-Valved Splittable Sheath Introducers.
• The recall is linked to a design defect that may prevent the sheath from splitting as intended during use.
• The action centers on product quality and regulatory compliance risks that could affect NasdaqGS:MMSI.

Merit Medical Systems (NasdaqGS:MMSI) supplies devices used across interventional cardiology, radiology, and vascular access, including components for dialysis catheter kits. A recall tied to a specific sheath design puts a fresh spotlight on product engineering, quality controls, and coordination with OEM customers that integrate Merit components into finished kits.

For you as an investor, the key question is how broad this recall is in terms of units, time frame, and contracts, and whether it leads to design changes or shifts in ordering patterns. Monitoring management’s commentary on remediation steps, regulatory dialogue, and any impact on manufacturing or inventory can help you assess how this episode fits into your longer term view of NasdaqGS:MMSI’s risk profile.

Stay updated on the most important news stories for Merit Medical Systems by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Merit Medical Systems.

The FDA-identified recall of Arrow International dialysis catheter kits that use Merit Medical’s 16F Dual-Valved Splittable Sheath Introducers puts product quality and OEM relationships in focus at the same time the company is talking up growth in higher margin platforms. For you, the key issue is not only the safety signal itself but also how contract manufacturers and hospital customers react versus alternatives from larger device peers such as Baxter, Becton Dickinson, or Boston Scientific. This sits against a backdrop where Merit has just reported first-quarter 2026 sales of US$381.88 million, net income of US$41 million, and slightly raised full year 2026 revenue guidance to a range of US$1.612b to US$1.634b. Those figures frame a business that is investing in oncology and other higher value areas while also absorbing recall related work. The question is whether the OEM dialysis exposure is small enough that any short term disruption, remediation costs, or potential reengineering stays contained relative to the broader portfolio, including recent additions such as View Point Medical’s OneMark oncology system and the Resilience esophageal stent.

How This Fits Into The Merit Medical Systems Narrative

• The recall highlights the importance of strong product engineering and regulatory engagement. This directly relates to the narrative’s focus on operational efficiency and quality as drivers of long term growth.
• It introduces an additional operational and regulatory overhang that could challenge the view that margins simply improve through automation and mix shift, especially if remediation or OEM contract changes add cost.
• The recall of the 16F sheath introducer in dialysis kits is not explicitly addressed in the existing narrative, which centers more on WRAPSODY reimbursement, tariffs, and acquisitions. Investors may therefore want to reassess how product quality events factor into the long term story.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Merit Medical Systems to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Recall related costs and any redesign of the 16F sheath introducer could affect margins if they require manufacturing changes, field actions, or concessions to OEM partners.
• ⚠️ Reputational or contract risk with OEM customers, if they reassess sourcing for dialysis components in favor of competitors, could weigh on volumes in that product segment.
• 🎁 Recent Q1 2026 results, including US$381.88 million in sales and US$41 million in net income, show the business has earnings capacity that may help absorb recall work without derailing broader plans.
• 🎁 Raised full year 2026 revenue guidance to US$1.612b to US$1.634b and expansion in oncology platforms through acquisitions and product launches give Merit multiple growth drivers beyond the recalled component.

What To Watch Going Forward

From here, watch how Merit quantifies the recall in terms of affected units, expected costs, and any changes in OEM contract terms, as well as whether the FDA or Arrow provide further updates on remediation progress. Pay attention to how management discusses quality systems, product redesign timelines, and whether dialysis related issues show up in order trends compared with faster growing oncology and endoscopy products. Any revision to 2026 guidance or commentary about margins, especially in the context of tariffs and reimbursement timing, will help you judge whether this recall remains a contained quality event or starts to influence the broader investment case.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Merit Medical Systems, head to the community page for Merit Medical Systems to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.